| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/28/2001 | WO1999063937A9 Multivalent macrolide antibiotics |
| 06/28/2001 | US20010005757 Meiosis regulating compounds |
| 06/28/2001 | DE19962936A1 New beta-aminoacid amide derivatives, are integrin antagonists useful for treating inflammatory, autoimmune or immunological disorders e.g. asthma, diabetes or rheumatoid arthritis |
| 06/28/2001 | DE19962329A1 New substituted 2-(phenylaminomethyl)-benzimidazoles, used as thrombin inhibitors, serine protease inhibitors, antithrombotic agents and intermediates |
| 06/28/2001 | DE19960640A1 Neue Stromelysin Inhibitoren New stromelysin inhibitors |
| 06/28/2001 | DE19959913A1 Acetylsalicylsäure enthaltendes transdermales System zur Behandlung von Migräne Aspirin-containing transdermal system for the treatment of migraine |
| 06/28/2001 | DE19959049A1 Kombination von Verbindungen, welche die biologischen Wirkungen von TNF-alpha und CD95L hemmen Combination of compounds, which inhibit the biological effects of TNF-alpha and CD95L |
| 06/28/2001 | DE19957065A1 Screening-Verfahren für Arzneistoffe A screening method for drugs |
| 06/28/2001 | CA2438477A1 An improved process for preparing simvastatin |
| 06/28/2001 | CA2399584A1 Non peptide tachykinin receptor antagonists |
| 06/28/2001 | CA2395520A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 06/28/2001 | CA2395513A1 Methods and compounds for inhibiting mrp1 |
| 06/28/2001 | CA2395471A1 4-[aryl(8-azabicyclo[3.2.1]octan-3-yl)]aminobenzoic acid derivatives |
| 06/28/2001 | CA2395406A1 Method for treating inflammation |
| 06/28/2001 | CA2395300A1 Novel compounds |
| 06/28/2001 | CA2395212A1 Polynucleotides and polypeptides encoded thereby |
| 06/28/2001 | CA2395202A1 Hydrazone and oxime derivatives of pyrrolidine as amp-specific phosphodiesterase inhibitors |
| 06/28/2001 | CA2395197A1 Acyl pseudodipeptides which carry a functionalised auxiliary arm |
| 06/28/2001 | CA2395136A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 06/28/2001 | CA2395108A1 Method of treating gastrointestinal tract disease with purinergic receptor agonists |
| 06/28/2001 | CA2395102A1 Human kinases |
| 06/28/2001 | CA2395007A1 Transporters and ion channels |
| 06/28/2001 | CA2394997A1 Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections |
| 06/28/2001 | CA2394877A1 Compounds and use thereof to modify transport across cell membranes |
| 06/28/2001 | CA2394860A1 Hypodermic needle with weeping tip and method of use |
| 06/28/2001 | CA2394852A1 Substituted pyrroles |
| 06/28/2001 | CA2394834A1 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2394789A1 Proteases |
| 06/28/2001 | CA2394633A1 Therapeutic and/or prophylactic agent for nervous system disorder |
| 06/28/2001 | CA2394624A1 Method for making 24(s)-hydroxyvitamin d2 |
| 06/28/2001 | CA2394604A1 Substituted acylhydroxamic acids and method of reducing tnf.alpha. levels |
| 06/28/2001 | CA2394589A1 Modulation of pax-2 for controlled apoptosis or survival of cells |
| 06/28/2001 | CA2394049A1 Vesicle trafficking proteins |
| 06/28/2001 | CA2393855A1 Homologues of human heparanase and splice variants thereof |
| 06/28/2001 | CA2393767A1 Molecules derived from mechanism based drug design |
| 06/28/2001 | CA2393756A1 Potassium channel inhibitors |
| 06/28/2001 | CA2393724A1 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| 06/28/2001 | CA2393646A1 Survivin promotion of angiogenesis |
| 06/28/2001 | CA2393367A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393363A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1b (ptp-1b) |
| 06/28/2001 | CA2393359A1 Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors |
| 06/28/2001 | CA2392873A1 Benzo[a]phenazin-11-carboxamide derivatives and their use as joint inhibitors of topomerase i and ii |
| 06/28/2001 | CA2392787A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2392554A1 Inhibitors of thrombin induced platelet aggregation |
| 06/28/2001 | CA2392150A1 Diamidine compounds as dna minor groove binders |
| 06/28/2001 | CA2392127A1 Tryptase inhibitors |
| 06/28/2001 | CA2392121A1 Tryptase inhibitors |
| 06/28/2001 | CA2391594A1 Trefoil domain-containing polynucleotides, polypeptides, and antibodies |
| 06/28/2001 | CA2390691A1 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 06/28/2001 | CA2389479A1 Butyne diol derivatives |
| 06/28/2001 | CA2388669A1 Inhibitors of farnesyl protein transferase |
| 06/28/2001 | CA2387579A1 Farnesyl transferase inhibitors |
| 06/28/2001 | CA2384326A1 Compositions and methods for l-nucleosides, l-nucleotides, and their analogs |
| 06/28/2001 | CA2363837A1 Use of aromatic polycyclic compounds as activators of ppars-type receptors in a cosmetic or pharmaceutical composition |
| 06/27/2001 | EP1110958A1 Alpha-arylethylpiperazine derivatives as neurokinin antagonists |
| 06/27/2001 | EP1110949A1 EP4 receptor selective agonists in the treatment of osteoporosis |
| 06/27/2001 | EP1110556A1 Preventives/remedies for multiple organ failure |
| 06/27/2001 | EP1109919A2 Rationally designed heparinases derived from heparinase i and ii |
| 06/27/2001 | EP1109918A2 Polypeptides, polynucleotides and uses thereof |
| 06/27/2001 | EP1109905A1 Genes encoding for the human and murine death inducer-obliterator-1 |
| 06/27/2001 | EP1109901A2 GABA B RECEPTOR SUBTYPES GABA B-R1c AND GABA B-R2 AND HETERODIMERS THEREOF |
| 06/27/2001 | EP1109900A1 Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor |
| 06/27/2001 | EP1109829A1 Human latent transforming growth factor beta binding protein 3 |
| 06/27/2001 | EP1109824A1 Novel bag proteins and nucleic acid molecules encoding them |
| 06/27/2001 | EP1109815A1 Chemokine receptor antagonists and methods of use therefor |
| 06/27/2001 | EP1109813A1 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
| 06/27/2001 | EP1109811A2 Pyrrolobenzodiazepines |
| 06/27/2001 | EP1109810A1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
| 06/27/2001 | EP1109809A1 Pyrroloquinolines for treatment of obesity |
| 06/27/2001 | EP1109804A1 Chemokine receptor antagonists and methods of use therefor |
| 06/27/2001 | EP1109800A1 Novel cdk inhibitors having flavone structure |
| 06/27/2001 | EP1109799A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors |
| 06/27/2001 | EP1109796A1 Telomerase inhibitors and methods of their use |
| 06/27/2001 | EP1109790A1 1, 2, 4-triazole-3-thione compounds |
| 06/27/2001 | EP1109787A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp) |
| 06/27/2001 | EP1109777A1 N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them |
| 06/27/2001 | EP1109573A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa |
| 06/27/2001 | EP1109571A2 Methods of treating hypertension and compositions for use therein |
| 06/27/2001 | EP1109569A2 Regulation of lung tissue by hedgehog-like polypeptides, and formulations and uses related thereto |
| 06/27/2001 | EP1109561A1 Promoters of neural regeneration |
| 06/27/2001 | EP1109559A2 Inhibition of pathogenic processes related to tissue trauma |
| 06/27/2001 | EP1109555A1 Novel angiogenesis inhibitors |
| 06/27/2001 | EP1109552A1 Novel dna-cleaving antitumor agents |
| 06/27/2001 | EP1109545A1 Fc RECEPTOR MODULATORS AND USES THEREOF |
| 06/27/2001 | EP1109543A1 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| 06/27/2001 | EP1109537A1 Immediate release tablet |
| 06/27/2001 | EP1109534A1 Quick release pharmaceutical compositions of drug substances |
| 06/27/2001 | EP1109529A1 Lipid extract of the skeletonema algae |
| 06/27/2001 | EP1109526A1 Improved stability for injection solutions |
| 06/27/2001 | EP0806953B1 Agent for acting upon bone formation disturbances containing potassium citrates, lactates and/or malates |
| 06/27/2001 | EP0734261B1 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
| 06/27/2001 | EP0701554B1 Novel compounds having a benzisoselen-azoline and -azine structure, method for preparing same and therapeutic uses thereof |
| 06/27/2001 | EP0690720B1 Therapeutic uses of bactericidal/permeability increasing protein products |
| 06/27/2001 | EP0660707B1 Amantadine and related compounds for use in the treatment of peripheral neuropathy |
| 06/27/2001 | CN1301298A Methods for prevention and treatment of cancer |
| 06/27/2001 | CN1301269A Template associated NPY Y2-receptor agonists |
| 06/27/2001 | CN1301265A Novel substituted arylhydroxamic acids as metalloproteinase inhibitors |
| 06/27/2001 | CN1301264A Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists |
| 06/27/2001 | CN1301260A Fumagillol derivatives and processes for preparing the same |
| 06/27/2001 | CN1301255A Heterocyclically substituted amides, their production and their use |